ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,245.37
-0.48%
Dow Jones
38,798.99
-0.22%
Gold vs US Dollar
2,293.845
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,377.34
0.06%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Genmab AS (GMAB)

  7. Genmab AS (GMAB) News

Genmab AS (GMAB)

Genmab AS
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GMAB
DateTimeSourceHeadlineSymbolCompany
03/06/202421:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
03/06/202414:00Business WireInvestigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)NASDAQ:GMABGenmab AS
02/06/202422:30Business WirePreliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular LymphomaNASDAQ:GMABGenmab AS
01/06/202415:00Business WireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)NASDAQ:GMABGenmab AS
28/05/202416:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
23/05/202422:00Business WireGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:GMABGenmab AS
21/05/202416:38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
21/05/202416:18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
21/05/202416:10Business WireGenmab Completes Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
14/05/202415:05Business WireGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressNASDAQ:GMABGenmab AS
13/05/202416:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
29/04/202423:40Business WireTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
29/04/202423:40Business WireFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
03/04/202406:35Business WireGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
11/03/202417:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
04/03/202418:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
04/03/202418:26Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
01/03/202422:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GMABGenmab AS
29/02/202416:47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
28/02/202416:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
27/02/202421:55Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
27/02/202412:45Business WireU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
26/02/202417:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
26/02/202415:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
22/02/202421:28Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GMABGenmab AS
20/02/202416:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
14/02/202420:42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
14/02/202418:49Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:GMABGenmab AS
14/02/202417:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
02/02/202411:45Business WireTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
 Showing the most relevant articles for your search:NASDAQ:GMAB

Your Recent History

LSE
POS
Plexus
LSE
SBTX
Skinbiotherapeutics
LSE
GKP
Gulf Keystone Petroleum
LSE
LLOY
Lloyds Banking
LSE
GDR
Genedrive
LSE
GOLD
LSE
AGL
Angle
LSE
BIRD
Blackbird
LSE
SOLG
Solgold
LSE
VAST
Vast Resources
LSE
PANR
Pantheon Resources
LSE
TW.
Taylor Wimpey
LSE
EEE
Empire Metals
LSE
SAR
Sareum
LSE
SRSP
Sirius Petroleum
LSE
INSG
Insig Ai
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved